

PROFILE

A seasoned corporate leader and Investment professional possessing over 18 years of comprehensive business and investment experience in leading Global Finance Institutions and Bio/Med-Tech Company. Leveraging on deep healthcare industry and capital market knowledge and scalability levers, I have helmed key businesses, engineered successful turnarounds for major business units, and achieved unrivalled ROI north of 500% by way of capital market campaigns. As a former Equity Research analyst, I have won multiple investment polling Awards across the breadth of my career. I thrive on high performing culture that consistently punch above its weight in volatile markets, I 'Cross-pollinate' leading edge knowledge and implement best practices to develop strategic markets for the future.

AREAS OF EXPERTISE

<i>Equity Research</i>	<i>Capital Markets Fund Raising</i>	<i>M&A Advisory</i>
<i>Internal Audit</i>	<i>Due Diligence Process</i>	<i>Start-ups Funding</i>
<i>Corporate Finance</i>	<i>Strategic Business Planning</i>	<i>Board Duties and Responsibilities</i>
<i>Medical Supply Chain</i>	<i>Investor Relations</i>	<i>Corporate Governance</i>
<i>Business Development</i>	<i>Succession Planning</i>	<i>Business Process Improvement</i>

KEY COMPETENCIES

- Analytical & conscientious, executing investment strategies to deliver M&A successes for current business.
- Proficient in Corporate Governance of Public Companies and Capital Market Regulatory & Compliance frameworks.
- Excellent cross-functional leadership & Industry networking skills along with the clear ability to negotiate at all levels.
- Proactive & adaptable with strong quantitative & analytical skills demonstrating high levels of integrity & work ethic.
- Effective financial decision-making; Strong experience of different commercial, competitive and business scenarios.

CAREER HISTORY

Chief Operating Officer, Bright Point Capital Pte Ltd

Mar 2020 – Current

Broadly speaking, I handle two functions in the business. Appointed as the representative of the Fund, I am one of the executives responsible for managing our investment portfolios. I oversee a team of professionals who have responsibilities ranging from managing and monitoring investment activity. The formulation of investment strategies and development of investment research are also part of my job function.

For the non-investment function, I am responsible for the investment selection and trade execution for the firm. This includes negotiating and handling contracts with outside counsel and fund services like prime brokerage, fund accounting and administration, managing internal legal and compliance, accounting and performance measurement, establishing processes and procedures for the operation. I am also responsible for post-trade processes, with focus on portfolio exposure and business cost optimization.

Executive Director, QT Vascular Limited
Feb 2015 – Aug 2019

Performing Board of Director fiduciary duties and ensuring corporate transparency with proper corporate governance.

I am responsible for Capital Market activities related to the Group and its associated interests, including JVs and other major investments structuring and executions. I serve as one of the key decision makers in the Group's M&A activities, with intensive participation in the due diligence process.

Aside from strategic planning for the Group, I look at how we support the Group's proprietary technology and intellectual properties, clinical trial processes in the US and regulatory licenses attainment from the Food and Drug Administration (FDA). Together with my finance team, I am involved in our internal and external audit processes. I am also responsible for all investor relation and corporate communication, having participated in various conferences and tradeshows locally and overseas (e.g. TCT conferences in the US).

Achievements/Transactions:

- M&A transactions of Group's assets to Medtronic (Jan 2018) and Teleflex (May 2018).
- Convertible Bond structuring and placement (2015 & 2016)
- Bridge loan structuring and placement (2016).

Associate Director, Equity Research, CIMB Securities, Singapore
Jun 2008 - Feb 2015

Lead analyst covering Healthcare, Biotech, Industrial, transport and situational investments. After the stint with Deutsche, I rejoined CIMB Securities, reprising the role I left previously. Despite the impact of the global financial crisis, I was able to spearhead various investment ideas that resulted in much needed fund raising for public companies and robust ROIs for institutional investors. The biggest and most successful work has to be the IHH healthcare IPO in 2012, where I have played the lead analyst role, supporting corporate finance work from pre-IPO and the Pre Deal Investment Education (PDIE). I am also credited for my in-depth research work on Bio/Med Tech companies.

Achievements:

- Awards and accolades (2014) include top 10 Asiamoney Singapore brokers ranking for Healthcare, Industrial and Utility sectors. Also rank top 3 stock pickers for Singapore Industrial sector in the prestigious Starmine award.
- Key projects/deals: IHH Healthcare IPO (Lead analyst 2012).
- Various equity placement deals for Environmental Protection listed companies from 2009-2011.

Associate, Global Credit Trading, Deutsche Bank
Sep 2007 – Jun 2008

Principal Financing & Structuring – Lead analyst for Greater China Real Estates related deals. Working within the Investment Banking team, I am responsible for identifying investment rationales and managing returns/risks profiles of existing deals.

I am also tasked with marketing of structured products to the bank's top-tiered institutional investor clients. For our Asia-Pac equity investment, I made recommendations for short term investment (Proprietary book).

Achievements:

- Engineered smooth exit strategy for "live" deals on hand
- Successfully generating short term trade ideas for Proprietary position.
- Attaining good financial returns collaborating with various investment groups (e.g. P/E, Hedge funds)

Vice President, Equity Research, CIMB-GK Securities, Singapore

2005 - Aug 2007

After the landmark merger between CIMB and GK Goh securities, I was hired by the new outfit as an Equity Research analyst. Responsible as the Lead analyst covering Healthcare, Pharmaceuticals, Consumers, Small and Mid-Caps names. I was able to address institutional clients' interests in investment decisions. I also played a key role in research marketing, road shows, various local and overseas investment conferences.

Achievements:

- Producing a few "good calls" that raised house's profile among clients. This serve to enhance clients traction and stickiness
- Key role in the initiating research products, including "Singapore Healthcare Conference in HK, London and NY"

Research Associate, Citigroup Smith Barney

2001 - 2005

My primary role is to render supported to the Head of Research in areas such as market valuation and equity strategies, other investment-related work, topics on capital management, corporate restructuring and government regulations.

Sector coverage included consumer, healthcare, land transportation, Asia Pac equity strategies and ASEAN small-to mid- capitalization stocks. Works financial modeling, forecasting, investment thesis, valuation methodologies, risks and returns analyses. I built database to perform analysis of all stocks under the Singapore Research coverage list. Responsible for equity research projects with local and regional counterparts.

Achievements:

- Research team II and AsiaMoney ranking.
- Built and integrated numerous materials that support the Research franchise.
- Developed various templates, models and materials for proprietary research works.

ACADEMIC HISTORY/CERTIFICATIONS

B.Sc. Finance (Honours), University of London

PROFESSIONAL MEMBERSHIP/ALUMNI

Member, Singapore Institute of Directors

MISCELLANEOUS INFORMATION

Language Skills: English and Chinese (Full Professional Fluency)

Nationality/Residency Status: Singaporean/Singapore

REFEREES

Malcolm Koo, Regional Head of Institutional Equities, CGS-CIMB

Tel: +65 [REDACTED]

Vincent Toe, CEO and Sponsor, ICH Gemini

Tel: +65 [REDACTED]

Dr. Foo Fatt Kah, Managing Director, Luminor Capital

Tel: +65 [REDACTED]

Alan Wang, Founder and managing partner, Asdew Acquisitions

Tel: +65 [REDACTED]

Victor Tan, CEO, First REIT

Tel: + [REDACTED]

**RICH CAPITAL HOLDINGS LIMITED
(THE "COMPANY")
RESUME OF INDEPENDNT DIRECTOR**

(A) PERSONAL DETAILS	
Name: Gary Ng Sin Tong	Nationality and Principal Country of Residence: Singaporean, Singapore
Chinese Name: 黄晨东	Marital Status: Married
NRIC / Passport No.: [REDACTED]	Address: [REDACTED]
Date of Birth / Age: [REDACTED] / 46	

(B) EDUCATIONAL AND PROFESSIONAL QUALIFICATIONS Please provide copies of education and professional qualifications (if available).			
From	To	Name of Educational or Professional Institution	Certificate or Qualification
1998	2000	University of London	Bsc. Banking & Finance
1997	1998	University of London	Diploma in Economics

(C) WORKING EXPERIENCE Please provide the detail from the beginning of the Director's/Key Executive Officer's working career to his/her current position.					
From	To	Employer	Position	Description of Responsibilities	Business
Mar 2020	Current	Bright Point Capital	COO	Operational matters, group investment strategy.	Fund Management
Feb 2015	Aug 2019	QT Vascular Limited	Executive Director/ Director of Capital Market	Board of Director function, capital market dealings.	Healthcare/Medical device

(D) DETAILS OF PRESENT DIRECTORSHIPS Please include the directorships of both private and listed companies.			
From	To	Company	Executive Director/Independent Director/Member of Committees
Feb 2020	Current	Wei Yuan Holdings Limited (HK)	Independent Non-Executive Director Audit Comm (Member) Nomination Comm (Member) Remuneration Comm (Chairman)

(E) DETAILS OF PAST DIRECTORSHIPS IN THE LAST 5 YEARS — SINCE APRIL 2015 Please include the directorships of both private and listed companies.			
From	To	Company	Executive Director/Independent Director/Member of Committees
Aug 2015	May 2019	QT Vascular Limited	Executive Director

(F) DETAILS OF AFFILIATIONS / PROFESSIONAL MEMBERSHIPS			
From	To	Organisation	Affiliation / Professional Membership
None			

(G) ACHIEVEMENTS OR AWARDS	
Year	Achievement / Award
None	

(H) PARTICULARS OF ANY FAMILY RELATIONSHIPS WITH OTHER DIRECTORS / KEY EXECUTIVES / OR SUBSTANTIAL SHAREHOLDERS OF THE COMPANY
N/A

(I) PARTICULARS OF ANY ARRANGEMENT / UNDERSTANDING WITH ANY SUBSTANTIAL SHAREHOLDER(S) OR SUPPLIER(S) OF THE COMPANY OR ITS SUBSIDIARIES PURSUANT TO WHICH YOU WERE APPOINTED A DIRECTOR / CHIEF EXECUTIVE OFFICER
N/A

Date: 18 May 2020

PrimePartners Corporate Finance Pte. Ltd.

16 Collyer Quay
#10-00 Income at Raffles
Singapore 049318

Attention: Mr Mark Liew
Chief Executive Officer and Executive Director

Dear Sirs,

RICH CAPITAL HOLDINGS LIMITED (THE "COMPANY")
- CONFIRMATION LETTER OF INDEPENDENCE

I hereby confirm that:

1. I **am not** an employee of the Company or any of the Related Companies and **have not** been employed by the Company or any of the Related Companies in the immediate past three financial years.
2. I **do not** have an Immediate Family who is, or has been in the immediate past three financial years, employed by the Company or any of the Related Companies whose remuneration is determined by the Company's Remuneration Committee.
3. I or an Immediate Family, in the current or immediate past financial year, **have not** provided to or received from, the Company or any of its subsidiaries, any Material Services or significant payments (excluding any fees for acting as a Director of the Company) which aggregated in excess of S\$50,000 over that financial year.
4. I or an Immediate Family, in the current or immediate past financial year, **am not/was not** a Substantial Shareholder or a partner in (with 5% or more stake), or an executive officer a director of, any organisation which provided to or received from the Company or any of its subsidiaries any Material Services or significant payments which aggregated in excess of S\$200,000 over that financial year.
5. I **am not** an Associate of any Director or Substantial Shareholder of the Company.
6. I **am not** accustomed or/nor under an obligation, whether formal or informal, to act in accordance with the directions, instructions or wishes of any of the Relevant Persons in relation to the corporate affairs of the Company.
7. I **do not** have any prior or current relationship with the Company, the Related Companies or the Relevant Persons, where such prior or current business dealings with the Company, the Related Companies or the Relevant Persons would include (i) any interest, direct or indirect, in the Company, the Related Companies or any Relevant Persons, or (ii) joint venture or strategic alliances owned jointly with the Company, the Related Companies or the Relevant Persons, that could interfere or be reasonably perceived to interfere with my exercise of independent business judgment in the best interests of the Company and in carrying out my role as an independent director and as a member of any Board committee(s) of the Company.
8. I am able to devote sufficient time to attend the relevant board and committee meetings of the Company and to carry out my duties and responsibilities as a Director of the Company.
9. I **have not** been a Director of the Company for an aggregate period of more than nine (9) years (whether before or after the listing of the Company).

10. All capitalised terms used herein which are not otherwise defined shall have the meaning set out in Annex A.

In view of the foregoing, I **am** to be considered an independent director of the Company.

Yours faithfully,



.....
Name: Gary Ng Sin Tong

Date: 18th May 2020

1. **“Related Companies”** means all or any of the following companies:
 - (a) Subsidiary of the Company;
 - (b) Holding company of the Company;
 - (c) Subsidiary of any such holding company; or
 - (d) Any company in which the Company or the Relevant Persons have an equity interest of 30% or more.
2. **“Relevant Persons”** means all or any of the following persons:
 - (a) Each Director and his Associates; and
 - (b) Each Substantial Shareholder and his Associates.
3. **“Associate”** as defined in the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist (“Catalist Rules”) means:
 - (a) in relation to any director, chief executive officer or substantial shareholder (being an individual) means:
 - (i) his Immediate Family;
 - (ii) the trustees, acting in their capacity as such trustees, of any trust of which he and his immediate family is a beneficiary or, in the case of a discretionary trust, is a discretionary object; and
 - (iii) any company in which he and his immediate family together (directly or indirectly) have an interest of 30% or more.
 - (c) in relation to a substantial shareholder or a controlling shareholder (being a company) means any other company which is its subsidiary or holding company or is a subsidiary of any such holding company or one in the equity of which it and/or such other company or companies taken together (directly or indirectly) have an interest of 30% or more.
4. **“Immediate Family”** as defined in the Catalist Rules, in relation to a person, means the person’s spouse, child, adopted child, step-child, sibling and parent.
5. **“Substantial Shareholders”** means persons who have an interest or interests in one or more voting shares (excluding treasury shares) in the company and the total votes attached to that share, or those shares, is not less than 5% of the total votes attached to all the voting shares (excluding treasury shares) of the company, in line with the definition set out in section 2 of the Securities and Futures Act (Chapter 289) of Singapore.
6. **“Directors”** means the directors of the Company as at the date hereof.
7. **“Material Services”** means services, which may include auditing, banking, consulting and legal services as provided under the Singapore’s Code of Corporate Governance 2018.